It’s time for another edition of Reading Roundup featuring the top blog posts of October 2017. Start off your week by catching up on what the pharmaceutical industry was reading in October.
The New Normal - Pharmaceutical Engineering Magazine Editorial
Gilead’s purchase of Kite Pharma, one of the companies developing chimeric antigen receptor (CAR) T-cells, on 28 August sent strong signals across the markets. Learn more about the FDA newly approved CTL019, Novartis’s CAR T-cell therapy.
Data Quality and Data Integrity: What is the Difference?
Data Integrity is defined by Wikipedia as “maintaining and assuring the accuracy and consistency of data over its entire life-cycle”. Data Quality is defined by GAMP® does not define data quality. Learn the difference between Data Quality and Data Integrity.
We Call It Charisma in A Can – Quality Culture in Pharma
The FDA asked us to measure quality parameters in our operations. Those metrics are presumed to reflect the underlying quality culture of an organization. Find out how Norm Howe believes managers are key to stronger quality culture.
UGA's Wided Najahi-Missaoui Granted First Women in Pharma Scholarship
Wided Najahi-Missaoui, MS, PharmD, doesn’t know the meaning of the word "can't." Wided is the first recipient of ISPE's Women in Pharma (WIP) award. Learn more on Wided Najahi-Missaoui’s professional journey.
“Engineering + Mentoring” for Women in Pharma
The community of Women in Pharma includes mentors, resources across all levels, and educational sessions that will be an enabler for career success and work life balance. During our Women in Pharma session we will looked at mentoring in engineering. Get more information The Women in Pharma session: “Career Strategies for Early Career Professionals”.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...
